Mass. General researchers discovered an unexpected reservoir of the immune cells called monocytes in the spleen and showed that these cells are essential to recovery of cardiac tissue in an animal heart attack model.
Unexpected reservoir of monocytes discovered in the spleen
Mouse study indicates immune cells from spleen may be essential in healing heart attack damage
It takes a spleen to mend a broken heart - that’s the conclusion of a surprising new report from researchers at the Massachusetts General Hospital (MGH) Center for Systems Biology, directed by Ralph Weissleder, MD, PhD. In the July 31 issue of Science the team reports how, in following up an intriguing observation, they discovered an unexpected reservoir of the immune cells called monocytes in the spleen and went on to show that these cells are essential to recovery of cardiac tissue in an animal heart attack model.
"Monocytes are known to serve as a central defense system against injury, and we found that monocytes released from the spleen go directly to the injured heart and participate in wound healing," says Matthias Nahrendorf, MD, PhD, a co-lead author of the study.
Monocytes are generated in the bone marrow, released into the blood and are known to accumulate at injured or infected tissues, where they differentiate into macrophages or dendritic cells. In investigating processes involved in the healing of ischemic heart tissue - the sort of injury produced in a heart attack - in mice, the research team was surprised to find more monocytes accumulating at the site of injury than would be found in the animals’ entire circulatory system. When they searched many types of tissue for the presence of cells with monocyte-specific molecules, they only found significant numbers of such cells in the spleen.
Monocytes in the spleen were identical in appearance, composition and function to monocytes in the blood. To investigate the splenic monocyte reservoir’s potential involvement in cardiac healing, the researchers used several new technologies. A newly developed microscopic technique allowed them to determine how and where monocytes are stored in the spleen - previously known to store red blood cells - and to study how monocytes are released in response to an experimentally-induced heart attack. A novel three-dimensional optical imaging technique (fluorescence molecular tomography, developed at the MGH Center for Molecular Imaging Research) allowed study of monocyte-mediated immune functions at the site of heart muscle injury.
In mice whose spleens were removed and replaced with a donor organ, an induced heart attack led to rapid increase of spleen-derived donor monocytes in the bloodstream and massive accumulation of donor cells at the site of injury. In animals from whom spleens were removed but not replaced, heart attack produced no significant monocyte increase in the bloodstream or in the heart. "With all these approaches together, we found that the monocytes that travel to the heart after a heart attack come directly from the spleen and that, without the splenic monocytes, the heart tissue does not heal well," says Filip Swirski, PhD, co-lead author of the Science report.
The investigators also found that the hormone angiotensin II, known to be released in response to a heart attack, is actively involved in the release of monocytes from the spleen. Identifying that pathway could lead to ways of manipulating the splenic monocyte reservoir to improve healing after a heart attack and potentially regulate other inflammatory situations. "We need to know whether this monocyte reservoir is important in other diseases - such as viral or bacterial infection, cancer or atherosclerosis - and understand how to precisely control storage and release of monocytes in a therapeutic setting, both of which we are currently investigating," says Mikael Pittet, PhD, senior author of the Science report.
Pittet and Nahrendorf are both assistant professors of Radiology at Harvard Medical School, and Swirski is an instructor in Radiology. Additional co-authors of the Science report are Martin Etzrodt, Moritz Wildgruber, Virna Cortez-Retamozo, Peter Panizzi, PhD, Jose-Luiz Figueiredo, MD, Rainer Kohler, PhD, Aleksey Chudnovskiy, Peter Waterman, Elena Aikawa, MD, PhD, Thorsten Mempel, MD, PhD, and Ralph Weissleder, MD, PhD, MGH Center for Systems Biology; and Peter Libby, MD, Brigham and Women’s Hospital. The study was supported by grants from the National Institutes of Health and the MGH Center for Systems Biology.
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $500 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.
Media Contacts: Sue McGreevey, 617 724-2764, email@example.com
U.S. News & World Report ranks Mass General #1 in New England and #2 in the nation based on our quality of care, patient safety and reputation in 16 clinical specialties.
Search the archive for previously published news articles, press releases and publications.
Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.